Rhode Island Lawmaker Failed to Disclose $21,000 in Kratom-Linked Travel Trips

Representative Kennedy amended his ethics filings Tuesday night to disclose two previously unreported kratom-linked trips worth a combined $21,000.

Representative Kennedy led the successful 2025 legislative push to legalize kratom in Rhode Island, but new disclosures reveal he accepted thousands of dollars in travel funding from industry-linked nonprofits that went unreported on his ethics filings at the time.

The Boston Globe reported that Kennedy failed to disclose two separate trips to Indonesia in 2023 and 2024, which were funded by organizations advocating for the plant’s legality.

State law requires public officials to disclose any out-of-state travel exceeding $250 if paid for by outside entities. While Kennedy had previously disclosed a $12,000 trip to Indonesia in 2022, the two subsequent excursions—costing a combined $21,000—were absent from his annual ethics reports until he amended them this past Tuesday night.

Kennedy told The Boston Globe that the omission was inadvertent and that there was “nothing nefarious to be inferred” from the situation.

The financial backing for these trips highlights the intense lobbying efforts surrounding the drug’s status. The International Plant and Herbal Alliance, a nonprofit supporting kratom legalization, covered nearly $15,000 for the July 2023 trip, according to the group’s president, Lora Romney.

A second trip in August 2024 was paid for by the Center for Plant Science and Health, which provided $6,000. These organizations are closely aligned with the American Kratom Association, which actively lobbied Rhode Island lawmakers to overturn the state’s 2017 ban.

The stakes for residents remain high as medical professionals express growing alarm over the accessibility of these products. While the legislation Kennedy sponsored includes strict labeling requirements and restricts sales to adults over 21, local health experts warn that the regulatory environment is struggling to keep pace.

Dr. Cecilia Fix, director of addiction medicine at Brown University Health, noted a “dramatic increase” in patients seeking help for kratom addiction over the last six months. She emphasized the danger of potent derivatives, stating, “7-OH is thought to be about 20 times more potent than morphine.”

The regulatory gap is further complicated by the state’s limited capacity for oversight. The Rhode Island Department of Health, which now oversees the licensing of retailers, currently lacks the funding to perform proactive laboratory testing or regular inspections.

Department officials said that they have requested an additional $200,000 in the upcoming state budget to enforce compliance. Meanwhile, the office of Governor-elect Helena Buonanno Foulkes has signaled that it intends to explore more stringent protections for public health upon taking office.

The ethics of the situation have drawn sharp criticism from transparency advocates. John Marion, executive director of Common Cause Rhode Island, argued that the travel was clearly intended to influence the legislative process.

“Representative Kennedy only received this travel because he’s a public official, so it’s obviously designed to try to influence him,” Marion said. Hilary Tesluck, executive director of End Kratom Addiction, has requested that the Rhode Island Ethics Commission investigate the matter to determine if Kennedy violated gift rules.

Defenders of the industry maintain that the trips were educational opportunities. “This was a perfect opportunity for government leaders to learn so they can pass laws based on their educational findings,” Romney told The Boston Globe.

Mac Haddow, the top lobbyist for the American Kratom Association, echoed this sentiment, asserting that his organization adheres to all legal requirements. Haddow, who serves on the board of the National Conference of State Legislatures, said that he introduced Kennedy to the issue and that the two have since developed a personal friendship.

As the debate continues, the legal status of specific kratom derivatives remains a moving target. While the natural leaf remains legal in Rhode Island, the Drug Enforcement Administration is expected to move toward restricting semi-synthetic products like 7-OH.

For now, the state’s health department continues to grapple with the reality of a market that has expanded rapidly since the 2025 legalization. “Our concerns about kratom that we’ve raised in the past are the same as they ever were,” said Neil Hytinen, chief of staff for the Department of Health.

Kennedy himself has voiced support for strengthening enforcement, telling The Boston Globe that if illicit substances are being sold, “I would advocate for more funding to assist the Department of Health to inspect locations where kratom is sold and to allow for law enforcement to have the ability to enforce the law.”

Whether those measures will satisfy those concerned about the influence of the industry on the legislative process remains an open question for the incoming administration.